Sun Pharma Advanced Research Company Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
SPARC reported its Q1 FY26 (quarter ended June 30, 2025) results with revenue from operations falling sharply to ₹964 lakhs from ₹1,681 lakhs in the same quarter last year, a drop of about 43%. Other income, however, jumped to ₹914 lakhs from ₹156 lakhs, lifting total income to ₹1,878 lakhs. The company posted a net loss of ₹5,187 lakhs (consolidated), an improvement from the ₹9,590 lakh loss in Q1 FY25, but still deeply in the red. Loss per share narrowed to ₹1.60 from ₹2.96. Other equity remains negative at ₹(24,940) lakhs, reflecting heavy accumulated losses. The auditor (S R B C & Co LLP) issued an unqualified limited review report. Importantly, the company disclosed that it has incurred cash losses in past and current quarters, and its going concern status continues to depend on a financial support letter from its promoter group entity.
Despite a narrower loss, the continued operating losses, negative net worth, and dependence on promoter support raise sustainability concerns for shareholders. The steep drop in core revenue is a negative signal, though reduced clinical trial and professional charges suggest cost rationalisation. Stock may remain volatile given ongoing reliance on promoter funding.